title: Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses.
abstract: BACKGROUND
  Retinoids have been shown to improve the manifestations of skin photodamage, including actinic keratoses.
  
  
  OBJECTIVE
  The efficacy and tolerability of isotretinoin 0.1% cream in the treatment of actinic keratoses were evaluated in a randomized, double-blind, placebo-controlled, parallel-group study.
  
  
  METHODS
  One hundred patients were randomly assigned to treatment with 0.1% cream or vehicle twice daily for 24 weeks to the face, the scalp, and the upper extremities. Patients were assessed every 4 weeks by the investigators, who counted and recorded the number of lesions in each treatment area. The 93 patients who had at least one postbaseline assessment were included for efficacy analysis. Local tolerability was evaluated at each study visit.
  
  
  RESULTS
  On the face, the reduction in number of actinic keratoses (mean +/- SEM) at the end of treatment was greater for patients treated with isotretinoin (3.9 +/- 0.6, i.e., 66% of patients with a reduction > 30%) than with placebo (1.7 +/- 0.5, i.e., 45% of patients with a reduction > 30%); this difference was statistically significant (p = 0.001). No significant drug effect was seen for lesions on the scalp or upper extremities. Mild to moderate local reactions with isotretinoin abated with reduced treatment frequency.
  
  
  CONCLUSIONS
  Our results suggest that isotretinoin 0.1% cream cannot compete with more rapid treatments of actinic keratoses. However, its effect on facial lesions may be beneficial during long-term treatment of associated sun-damaged skin.
authors.affiliation: Department of Dermatology, Hôpital Saint Charles, Montpellier, France.
authors.forename: M
authors.initials: M
authors.lastname: Alirezai
authors.forename: P
authors.initials: P
authors.lastname: Dupuy
authors.forename: P
authors.initials: P
authors.lastname: Amblard
authors.forename: B
authors.initials: B
authors.lastname: Kalis
authors.forename: P
authors.initials: P
authors.lastname: Souteyrand
authors.forename: A
authors.initials: A
authors.lastname: Frappaz
authors.forename: E
authors.initials: E
authors.lastname: Sendagorta
mesh_terms: D000287:Administration, Topical; D001132:Arm; D004311:Double-Blind Method; D005148:Facial Dermatoses / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D007642:Keratosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D012536:Scalp Dermatoses / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D013472:Sunlight / Q000009:adverse effects*
chemical_list: D015474:Isotretinoin